Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Vir Biotechnology, retaining the price target of $15.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Patrick Trucchio has given his Buy rating due to a combination of factors including significant advancements in Vir Biotechnology’s pipeline and strategic positioning in both infectious disease and oncology. The company has made pivotal progress in its hepatitis delta virus (HDV) program, with the ECLIPSE trials fully enrolling and showcasing potential best-in-class agents in a market with limited treatment options.
Additionally, Vir’s oncology pipeline is gaining traction, with new clinical programs and promising early data supporting the effectiveness of their proprietary platform. The company’s strong cash position, extending into mid-2027, further supports its ability to capitalize on these developments. The combination of these factors, along with multiple upcoming data catalysts, underpins the Buy rating and the $15 price target for Vir’s stock.
In another report released yesterday, Barclays also maintained a Buy rating on the stock with a $31.00 price target.
Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VIR in relation to earlier this year.